Relay Therapeutics announced positive interim data for its drug candidate RLY-2608 in treating patients with PI3Kα-mutated, HR+, HER2- breast cancer. The data showed clinically meaningful progression-free survival and a high clinical benefit rate in patients receiving RLY-2608 in combination with fulvestrant. The drug was generally well-tolerated, and the company plans to pursue regulatory approval for lirafugratinib in cholangiocarcinoma.